Which funds bought or sold SYK in Q3 2026?
Stryker Corporation. 8 funds bought, 9 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$421M. See also what famous investors say about SYK.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Wellington+$511M
- Ameriprise+$335M
- D. E. Shaw+$141M
- Arrowstreet+$127M
- BalyasnyNEW+$105M
- Man Group+$48M
- Baillie GiffordNEW+$17M
- PRIMECAP+$10M
- JPMorgan−$1.4B
- Bank of America−$539M
- AllianceBernstein−$235M
- Morgan Stanley−$226M
- JennisonOUT−$102M
- Vanguard−$82M
- Fundsmith−$66M
- Wells Fargo−$55M
- Adage−$49M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (8)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Wellington Asset manager | Added+22.7% | +$511M | $2.8B |
| Ameriprise Asset manager | Added+37.3% | +$335M | $1.2B |
| D. E. Shaw Quant & multi-strategy | Added+189.1% | +$141M | $215M |
| Arrowstreet Quant & multi-strategy | Added+14.1% | +$127M | $1.0B |
| Balyasny Quant & multi-strategy | New | +$105M | $105M |
| Man Group Quant & multi-strategy | Added+1646.9% | +$48M | $51M |
| Baillie Gifford Growth / crossover | New | +$17M | $17M |
| PRIMECAP Growth / crossover | Added+5.5% | +$10M | $197M |
Sold (9)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| JPMorgan Bank & broker | Trimmed-28.9% | −$1.4B | $3.4B |
| Bank of America Bank & broker | Trimmed-43.9% | −$539M | $689M |
| AllianceBernstein Asset manager | Trimmed-17.3% | −$235M | $1.1B |
| Morgan Stanley Bank & broker | Trimmed-13.8% | −$226M | $1.4B |
| Jennison Growth / crossover | Sold out | −$102M | — |
| Vanguard Index giant | Trimmed-3.6% | −$82M | $2.2B |
| Fundsmith Value investor | Trimmed-8.3% | −$66M | $736M |
| Wells Fargo Bank & broker | Trimmed-8.4% | −$55M | $608M |
| Adage Hedge fund | Trimmed-57.5% | −$49M | $36M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.